Northwest Biotherapeutics Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northwest Biotherapeutics Inc.

NWBO 0.231

-3.7%

Nov 17 3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	7/11/2007 11:18:59 PM
	of 759

Collins Stewart analyst Navid Malik estimates that the product will generate $15m (€11m) next year (treating just 200 patients) MY EDIT so - if I use my calculator correctly that works out to 15,000,000 / 200 = $75,000 per patient vaccine cost which means a net profit for NWBT of $3.3m, while revenues for 2009 are expected to reach $36m with a $11.5m net profit for the company. "The approval is also validation of what may come to be realised as one of the most important platform technologies in the world of cancer therapeutics," said Malik in a research note. "The holy grail of having a vaccine which is personalised to the patients own tumour with minimal or no side effects, and substantial efficacy over current cancer drugs has been realised." us-pharmatechnologist.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next